In early November 2019, the FDA undated a previous safety communication about the potential of biotin to significantly interfere with diagnostic tests. The update reiterates the warning to lab … [Read more...]
New Product Development: FDA Issues Final Guidance on IVD Oncology Trials
On Oct. 10, 2019, the FDA finalized guidance on an optional streamlined submission process to determine whether use of an investigational in vitro diagnostic (IVD) in an oncology clinical trial is … [Read more...]
LDTs: FDA Gets Tough with Non-Approved PGx Testing Claims
The FDA has apparently set its enforcement sights on Laboratory Developed Tests (LDTs) that claim to predict patients' responses to medications. It began in 2018, when the FDA warned consumers and … [Read more...]
Inside Washington: What’s Going on with Regulation of LDTs?
Although things appear to be quiet, progress is actually being made in the quest to create workable regulation of Laboratory Developed Tests (LDTs) developments. Here's a rundown of the latest … [Read more...]
New FDA Guidance Tells IVD Makers How to Test for Biotin Interference
On June 13, the FDA issued a draft guidance explaining how makers of in vitro diagnostic devices (IVDs) should perform biotin interference testing and communicate testing results to labs, clinicians … [Read more...]
FDA Watch: Agency Okays Marketing of Zika Test for First Time
Over the past several years, the FDA has issued Emergency Use Authorization (EUA) for over a dozen different tests for Zika. But on May 23, 2019, the FDA did something it had never done before: It … [Read more...]
Case of the Month: FDA Issues Warning Letter for Unapproved Changes to Approved Assay
As a rule of thumb, FDA approvals are a snapshot applicable only to the product as it exists at the time of review and approval. So, when the product undergoes significant changes, it often triggers … [Read more...]
Compliance Alert: FDA Warning Letter to Inova Genomics Laboratory
By Danielle Sloane bio and Elaine Naughton bio Despite it being a continual topic of discussion, the Food and Drug Administration ("FDA") enforcement in the realm of laboratory developed tests … [Read more...]
Gottlieb Resigns as FDA Chief: Lab Industry Loses a Good Frenemy
Scott Gottlieb, M.D., is resigning as FDA commissioner, the position he's held since 2017. But while his reign lasted just two years, Gottlieb has been a longtime friend and foe of the lab industry … [Read more...]
FDA Watch: Latest Plan to Simplify 510(k) Premarket Review of New Tests
While everybody agrees that the FDA 510(k) premarket review pathway is antiquated and in desperate need of an overhaul. For several years, the FDA, Congress and lab industry have been working together … [Read more...]